ExodusPoint Capital Management LP Invests $1.15 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

ExodusPoint Capital Management LP acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 29,870 shares of the company's stock, valued at approximately $1,153,000. ExodusPoint Capital Management LP owned about 0.05% of Protagonist Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Franklin Resources Inc. grew its holdings in Protagonist Therapeutics by 127.2% during the third quarter. Franklin Resources Inc. now owns 81,591 shares of the company's stock valued at $3,782,000 after purchasing an additional 45,674 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Protagonist Therapeutics by 3,099.4% during the 3rd quarter. Principal Financial Group Inc. now owns 320,832 shares of the company's stock worth $14,437,000 after buying an additional 310,804 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in Protagonist Therapeutics by 36.7% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company's stock valued at $8,340,000 after buying an additional 58,002 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Protagonist Therapeutics in the 4th quarter worth $2,016,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Protagonist Therapeutics by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company's stock worth $22,327,000 after acquiring an additional 12,906 shares during the last quarter. 98.63% of the stock is owned by institutional investors.

Remove Ads

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 4,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the transaction, the director now directly owns 13,130 shares in the company, valued at $712,302.50. This represents a 23.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total value of $1,700,850.36. Following the transaction, the insider now directly owns 83,892 shares of the company's stock, valued at approximately $4,676,140.08. The trade was a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 64,776 shares of company stock valued at $3,585,010. 5.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Protagonist Therapeutics in a research report on Thursday, April 10th. Truist Financial raised their target price on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. JPMorgan Chase & Co. upped their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. BTIG Research set a $73.00 price objective on shares of Protagonist Therapeutics in a research note on Monday, March 3rd. Finally, BMO Capital Markets boosted their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $65.44.

Protagonist Therapeutics Stock Up 2.9 %

PTGX traded up $1.30 during trading on Tuesday, reaching $46.33. 677,039 shares of the company's stock were exchanged, compared to its average volume of 832,247. The company has a market capitalization of $2.84 billion, a P/E ratio of 17.45 and a beta of 2.30. The business has a 50 day moving average price of $44.19 and a 200 day moving average price of $42.74. Protagonist Therapeutics, Inc. has a fifty-two week low of $24.22 and a fifty-two week high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $2.07. The company had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. As a group, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.